

OTC Markets

Joining us today, we have Dr. Lior Shaltiel. Did I pronounce that correctly?

Lior Shaltiel

Yeah, that's correct.

OTC Markets

All right. Thank you. CEO of Nurexone Biologic Inc, which trades on the OTCQB venture market under the ticker NRXBF and on the TSXV under the ticker NRX. Welcome.

Lior Shaltiel

Hey, good to be here.

OTC Markets

Thank you. Thank you. So, to start, Dr. Shaltiel, can you tell us a little bit about yourself and, you know, what drew you to Norexone Biologic, and how it all got started?

Lior Shaltiel

Sure. So, my education is a chemical engineer. I had also a PhD in pharmacology. I'm specialized in drug delivery system and exosomes, what we produce and modify and make it as a drug, is the ultimate drug delivery system, in my opinion. I worked many years with liposomes and LNPs. And I think what we get from exosomes or extracellular vesicles are a golden bullet for medicine. We have a drug delivery system that has therapeutic effect and it can accumulate in the area of damage where there is inflammation. We can speak about it later.

OTC Markets

Yeah. So, um you know, you just mentioned your exosome based therapies. What's the core mission behind Nurexone's work and what sets those exosome based therapies apart from other companies?

Lior Shaltiel

Sure. We are a company that focuses on neurology. We want to have a solution for unmet- huge unmet needs of regeneration of neurons in the central nervous system. When you are injured, let's say car accident, ski, sport, and you are

injured and you cannot feel your legs, and you know that it's irreversible, we think that we can reverse the situation and maybe help you to gain back some of your function that you lose due to the injury. It can be in the spinal cord injury. It can be optic nerve damage. This is the same system. this is Optic nerve is part of our nerves, brain nerves. It can be facial nerves that we show recently a results and other indication, let's say stroke, traumatic brain injury. So the message here, we have a solution to regenerate neurons okay and create functional recovery after injury in the acute phase. I want to say in the acute phase, because this is the best chance to reverse what happened.

OTC Markets

So, you mentioned ah spinal cord injuries and optic nerve. Your lead candidate, XOP10, has shown promise for spinal cord injuries. I'm not a science guy. I don't know how many of our listeners are, but can you walk us through the science and you know some of the progress that you've seen with this?

Lior Shaltiel

Yes. So I want to say that the company came from innovation research from university. Two universities that joined forces together, Professor Daniel Offen from Tel Aviv University and Professor Shulamit Levenberg from the Technion had a joint project, and they wanted to to have regeneration of neurons in his spinal cord injury. After a few generations of this product, they find out that a rat, after a full transaction, for cut completely the spinal cord and get the therapy of XOP10, exosomes loaded with sRNA against the protein called p10, we can talk about sequence later, show that the rat, after the spinal cord injury, could walk again. And those this is the wow effect that all this a science came from. We established a company to work with from this innovation. We base our knowledge on very strong IP, intellectual properties, covering several elements, how to produce those tiny vesicles. I'm talking about nanometers, tiny vesicles called exosomes in a three dimension bioreactor. Including composition of matter, how to load them with our siRNA, and what to load inside. So also the siRNA sequence that we target in order to reduce the amount of this protein called P10 is also patented.

OTC Markets

And so tell me more about this protein, P10. What does it do? What's it for?

Lior Shaltiel

I will give you an analogy. What is P10? P10 is like a policeman. Okay. He is

responsible, it's very important, important and responsible if the cell will proliferate, grow, and you know continue splitting into more and more cells, or to stop. Okay, and this is exactly why it's a very important protein for a tumor. It's a tumor suppressor. If cancer cells were to proliferate without any limitation, he will reduce this protein. We are taking this knowledge and say, okay, let's say that we want to reduce it, but very temporarily and very locally, together with our exosomes. And this will actually bring the cells to grow again. Okay, so we are actually reducing the police forces in on the street and creating a good crime. Okay, we're asking the cells to proliferate, okay, when it's needed after damage. Because if there is damage, there are neurons that start to die. And we want to make sure that the neurons that are still there will be able to grow a new axon, connect, and have a functional recovery with a readout of a sensoric or motor function increase.

OTC Markets

And, so, I read in some recent news that Nurexone is getting even closer to clinical trials. What's that process like? How is it? How far away are we from that?

Lior Shaltiel

When you produce a drug, it's a very long process. We are working several years already for having the CMC, the chemical manufacturing control of our product to make it, you know, as the FDA request. We are working on a synopsis, how the clinical study will look like. And this what happened last month. Professor Nahshon Knoller, part of our Scientific Advisor Board, who is actually leading the Spinal cord project was invited to give a lecture, I think one of the first preclinical companies that present in the American Association of the Spinal Cord Injury, but next to Phoenix, and he presents what is our thoughts and our plans, how the clinical study will be like. We are talking about very small side of size of a numbers of patients since it's often drug designation. We have an often drug designation from the FDA and also from Europe, from IMA. So in this case, you don't need to recruit so many patients. This will facilitate the time that we can present results. and And this is it was a huge honor for Nurexone to be part of one of the lectures during this special conference.

OTC Markets

Now, ah perhaps the answer is they should be looking out for results from these clinical trials. But if I were to ask what investors you know that look at the OTCQB market that are that are watching your stock, what should they be watching out for in the next couple of months or next year? You know, I understand it takes a while with all these trials.

Lior Shaltiel

Sure. I think the take-home message here and that I wanted to say that Nurexone is a unique creature. We are, yes, a biopharmaceutical company that develops a drug, but we have a very unique business approach. Why? Because not that we have only the XOP10 as lead product, product. This product is not going to be only for one indication or several indications. We discussed it today, spinal cord injury, optic nerve damage, like in glaucoma, facial nerves, and more indications. So we have several indications for one product, but we don't have only this product. We have other products in our portfolio, including a partnership with a cell therapy called IntelliJX in Canada trying to have a combined therapy. That's one. Second, we acquired last December 2024, our master cell bank, which is the fully characterized GMP approved FDA cell, the cell bank. And we are using bone marrow, mesenchymal cell cells, and this will allow us to produce our own demand of exosomes. Here in the US, and also to supply the demand for exosomes in different indication or different use, for example, for aesthetic and cosmetic. And this is a huge opportunity for investors to invest in a hybrid business model of Nurexone. We have revenue stream as a preclinical company still okay from exosome production as a B2B business. And, a company that will have a fluctuation of value due to the fact that they are- we are going from a preclinical stage to a clinical stage. And then you know valuation of a company from a preclinical stage can go from five to 10 times more between preclinical stage to a clinical stage. This is our value proposition and I think it's very attractive to investors in the US. We see very um our majority of the investors actually are Germans. And, we can see hundreds of thousands of shares trade every day in Germany. And I think what we see there should be here in a larger market of the world in the US.

OTC Markets

Well, let's see. Let's see what happens in the coming months. And, you know, we hopefully it's only up from here, right?

Lior Shaltiel

Yes.

OTC Markets

All right. So, we are coming up on time here. I always like to ask if listeners or investors want to learn more, or want to follow updates, what's the best way to stay on top of your company, your story, or if they want to talk to you to learn more, what's the best way to contact you?

Lior Shaltiel

Sure. So, we are very transparent company. Our website is full of details, including the Investor Hub. You can see their research analysts. You can see the press release. We can see the all the legal requirement documents like financial reports and MD&A. We have the science there, different information about the indication that we go, the team. We are also working on the social media like any company now. We are very strong in LinkedIn. We have more than 4,000 followers on LinkedIn. I think it's amazing for you know young company. We have a YouTube. We just shared a new video of the company. And of course, you can also approach by email. You know, all the details are in the website.

OTC Markets

Wonderful. Dr. Shaltiel, thank you very much for joining us today. Again, we had Dr. Lior Shaltiel, CEO of Nurexone Biologic Inc., which trades on the OTCQB venture market on the ticker NRXBF. Thanks a lot for joining us.

Lior Shaltiel

Yeah, lovely being here.

**This is an autogenerated transcript and may contain typos.*